pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
the cabinet
Drugs
8,127
products tracked
★ save view
↓
export CSV
search
phase
all
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
sort
catalysts
recent
name
therapeutic area
all
Oncology
1831
Infectious Disease
718
Cardiology
425
Pulmonology
396
Immunology
371
Ophthalmology
368
Dermatology
300
Women's Health
view
list
cards
Phase 2
MP-0712
Neuroendocrine Tumors
$MOLN
MOLECULAR PARTNERS AG
0
catalysts
Phase 2
MP-101
dimiracetam [INN]
Amyotrophic Lateral Sclerosis
Mitochon Pharmaceuticals Inc
0
catalysts
Phase 2
MP-1032
Coronavirus Disease 2019 (COVID-19)
MetrioPharm AG
0
catalysts
Phase 2
MPB-1734
← prev
page 125 of 271
next →
131
Pain
89
Neurology
1
Solid Tumor
MegaPro Biomedical Co Ltd
0
catalysts
Preclinical
MPB-2354
Rheumatoid Arthritis
MegaPro Biomedical Co Ltd
0
catalysts
Phase 3
MPC-06ID
rexlemestrocel-L
Chronic Low Back Pain (CLBP)
$MESO
MESOBLAST LTD
0
catalysts
pre_registration
MR-107A02
meloxicam
Post-Operative Pain
Prostaglandin G/H synthase 2
$VTRS
Viatris Inc
0
catalysts
Phase 3
MR-142
phentolamine mesylate
Nyctalopia (Night Blindness)
Adrenergic receptor alpha
$VTRS
Viatris Inc
0
catalysts
Phase 2
MRG-002
Gastric Cancer
Shanghai Miracogen Inc
0
catalysts
Phase 2
MRG-004A
Solid Tumor
Shanghai Miracogen Inc
0
catalysts
Phase 2
MRM-3379
Fragile X Syndrome
$MIRM
Mirum Pharmaceuticals, Inc.
0
catalysts
Phase 2
MRT-2359
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
$GLUE
Monte Rosa Therapeutics, Inc.
0
catalysts
Phase 1
MRT-6160
Axial Spondyloarthritis
$NVS
NOVARTIS AG
0
catalysts
Phase 1
MRT-8102
Inflammation
$GLUE
Monte Rosa Therapeutics, Inc.
0
catalysts
Phase 1
MRX-2843
Non-Small Cell Lung Cancer
Meryx Inc
0
catalysts
Phase 1
MRX-8
Acinetobacter Infections
MicuRx Pharmaceuticals Inc
0
catalysts
MS CONTIN
MS CONTIN (MORPHINE SULFATE)
Purdue Pharma LP
0
catalysts
Preclinical
MSC-2
Optic Neuritis
SanBio Co Ltd
0
catalysts
Preclinical
MSCKD
Acute Renal Failure (ARF) (Acute Kidney Injury)
Orgenesis Inc
0
catalysts
Phase 1
MT-101
Parkinson's Disease
MThera Pharma Co Ltd
0
catalysts
Phase 2
MT-125
Glioblastoma Multiforme (GBM)
Myosin Therapeutics Inc
0
catalysts
Phase 2
MT-2990
Endometriosis
Tanabe Pharma Corp
0
catalysts
Phase 2
MTG-201
Prostate Cancer
Momotaro-Gene Inc
0
catalysts
Phase 1
MTI-201
Metastatic Uveal Melanoma
Modulation Therapeutics Inc
0
catalysts
Phase 2
MTL-CEBPA
Hepatocellular Carcinoma
Mina Therapeutics Ltd
0
catalysts
Phase 2
MTX-001
Venous Leg Ulcers (Crural Ulcer)
Merakris Therapeutics Inc
0
catalysts
Phase 2
MTX-463
Idiopathic Pulmonary Fibrosis
Eli Lilly and Co
0
catalysts
Phase 2
MTX-652
Acute Renal Failure (ARF) (Acute Kidney Injury)
Mission Therapeutics Ltd
0
catalysts
MUCINEX DM MAXIMUM STRENGTH
MUCINEX DM MAXIMUM STRENGTH (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE)
RB HLTH
0
catalysts
MUCUS DM
MUCUS DM (DEXTROMETHORPHAN HBR, GUAIFENESIN)
PERRIGO R AND D
0
catalysts
